Journal of Veterinary Clinics (한국임상수의학회지)

The Korean Society of Veterinary Clinics (한국임상수의학회)
권호 표지

Susceptibilities of Methicillin-Resistant Staphylococcus aureus (MRSA) Isolated from Milk of Bovine Mastitis to Antibiotics Combined with Sulbactam

젖소 유방염에서 분리된 메티실린 내성 황색포도상구균에 대한 항생제와 Sulbactam 병합의 항균효과

  • Published : 2008.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Various kinds of antibiotic intramammary infusions are used for treatment of bovine mastitis. As antibiotic-resistant bacteria are increased, the therapeutic rate for bovine mastitis is decreased. The goal of this research is to detect significant synergic effects of combination of antibiotics with sulbactam, $\beta$-lactamase inhibitor, on methicilin-resistant Staphylococcus aureus (MRSA). We used 5 strains of MRSA isolated from bovine mastitis with clinical and subclinical signs. All of the bacteria isolated had resistance to oxacillin and showed multi-resistant patterns in the antimicrobial susceptibility tests. Minimal bactericidal concentrations of ampicillin, amoxicillin, cephalexin, ampicillin/sulbactam(2:1), amoxicillin/sulbactam (2:1), and cephalexin/sulbactam (1:1) were measured according to broth microdilution method suggested by National Committee for Clinical Laboratory Standards (NCCLS, M31-A2) to compare the synergic effects of sulbactam combination with each antibiotic alone. Ampicillin and amoxicillin showed synergic antibacterial activity to 4 and 3 respectively in 5 strains of MRSA in combination with sulbactam. This study demonstrates that ampicillin/sulbactam and amoxicillin/sulbactam can be therapeutic choices for mastitis associated with MRSA.

Keywords

References

  1. Akalin HE. The role of beta-lactam/beta-lactamase inhibitors in the management of mixed infections. Int J Antimicrob Agents 1999; 12: S15-S20 https://doi.org/10.1016/S0924-8579(99)00087-4
  2. Dajani A. Use of ampicillin/sulbactam and sultamicillin in pediatric infections: a re-evaluation. J Int Med Res 2001; 29: 257-269 https://doi.org/10.1177/147323000102900401
  3. Erskine R, Cullor J, Schaellibaum M, Yancey B, Zecconi A. Bovine mastitis pathogens and trends in resistance to antibacterial drugs. National Mastitis Council Proceedings 2004; 400-413
  4. Erskine RJ, Walker RD, Bolin CA, Bartlett PC, White DG. Trends in antibacterial susceptibility of mastitis pathogens during a seven-year period. J Dairy Sci 2002; 85: 1111-1118 https://doi.org/10.3168/jds.S0022-0302(02)74172-6
  5. Finegold SM. In vitro efficacy of beta-lactam/beta-lactamase inhibitor combinations against bacteria involved in mixed infections. Int J Antimicrob Agents 1999; 12: S9-S14 https://doi.org/10.1016/S0924-8579(99)00086-2
  6. Gentilini E, Denamiel G, Betancor A, Rebuelto M, Rodriguez Fermepin M, De Torrest RA. Antimicrobial susceptibility of coagulase-negative staphylococci isolated from bovine mastitis in Argentina. J Dairy Sci 2002; 85: 1913-1917 https://doi.org/10.3168/jds.S0022-0302(02)74267-7
  7. Gentilini E, Denamiel G, Llorente P, Godaly S, Rebuelto M, DeGregorio O. Antimicrobial susceptibility of Staphylococcus aureus isolated from bovine mastitis in Argentina. J Dairy Sci 2000; 83: 1224-1227 https://doi.org/10.3168/jds.S0022-0302(00)74988-5
  8. Guinane CM, Sturdevant DE, Herron-Olson L, Otto M, Smyth DS, Villaruz AE, Kapur V, Hartigan PJ, Smyth CJ, Fitzgerald JR. Pathogenomic analysis of the common bovine Staphylococcus aureus clone (ET3): emergence of a virulent subtype with potential risk to public health. J Infect Dis. 2008; 197: 205-213 https://doi.org/10.1086/524689
  9. Hashisaki PA, Jacobson JA. Characteristics, control, and treatment of methicillin-resistant Staphylococcus aureus infections. Clin Pharm 1982; 1: 343-348
  10. Hirano L, Bayer AS. Beta-Lactam-beta-lactamase-inhibitor combinations are active in experimental endocarditis caused by beta-lactamase-producing oxacillin-resistant staphylococci. Antimicrob Agents Chemother 1991; 35: 685-690 https://doi.org/10.1128/AAC.35.4.685
  11. Janosi S, Huszenicza A, Horvath T, Gemes F, Kulcsar M, Huszenicza G. Bacteriological recovery after intramuscular or intracisternal spiramycin-based drying-off therapy. Acta Vet Hung 2001; 49: 155-162 https://doi.org/10.1556/AVet.49.2001.2.4
  12. Juhasz-Kaszanyitzky E, Janosi S, Somogyi P, Dan A, van der Graaf-van Bloois L, van Duijkeren E, Wagenaar JA. MRSA transmission between cows and humans. Emerg Infect Dis 2007; 13: 630-632 https://doi.org/10.3201/eid1304.060833
  13. Kazmierczak A, Duez JM, Pechinot A, Nordmann P, Labia R. In vitro bactericidal activity of sulbactam plus ampicillin against methicillin-resistant Staphylococcus aureus. Rev Infect Dis 1986; 8: S549-S554 https://doi.org/10.1093/clinids/8.Supplement_5.S549
  14. Kerro Dego O, van Dijk JE, Nederbragt H. Factors involved in the early pathogenesis of bovine Staphylococcus aureus mastitis with emphasis on bacterial adhesion and invasion. A review. Vet Q 2002; 24: 181-198 https://doi.org/10.1080/01652176.2002.9695135
  15. Kim WJ, Park SC. Bacterial resistance to antimicrobial agents: an overview from Korea. Yonsei Med J 1998; 39: 488-494 https://doi.org/10.3349/ymj.1998.39.6.488
  16. Kwon NH, Park KT, Jung WK, Youn HY, Lee Y, Kim SH, Bae W, Lim JY, Kim JY, Kim JM, Hong SK, Park YH. Characteristics of methicillin resistant Staphylococcus aureus isolated from chicken meat and hospitalized dogs in Korea and their epidemiological relatedness. Vet Microbiol 2006; 117: 304-312 https://doi.org/10.1016/j.vetmic.2006.05.006
  17. Makovec JA, Ruegg PL. Antimicrobial resistance of bacteria isolated from dairy cow milk samples submitted for bacterial culture: 8,905 samples (1994-2001). J Am Vet Med Assoc 2003; 222: 1582-1589 https://doi.org/10.2460/javma.2003.222.1582
  18. McDougal LK, Thornsberry C. New recommendations for disk diffusion antimicrobial susceptibility tests for methicillinresistant (heteroresistant) staphylococci. J Clin Microbiol 1984; 19: 482-488
  19. Mealey KL. Penicillins and beta-lactamase inhibitor combinations. J Am Vet Med Assoc. 2001; 218: 1893-1896 https://doi.org/10.2460/javma.2001.218.1893
  20. Mitchell JM, Griffiths MW, McEwen SA, McNab WB, Yee AJ. Antimicrobial drug residues in milk and meat: causes, concerns, prevalence, regulations, tests, and test performance. J Food Prot 1998; 61: 742-756 https://doi.org/10.4315/0362-028X-61.6.742
  21. Moon JS, Lee AR, Kang HM, Lee ES, Kim MN, Paik YH, Park YH, Joo YS, Koo HC. Phenotypic and genetic antibiogram of methicillin-resistant staphylococci isolated from bovine mastitis in Korea. J Dairy Sci 2007; 90: 1176-1185 https://doi.org/10.3168/jds.S0022-0302(07)71604-1
  22. National Mastitis Council. Laboratory Handbook on Bovine Mastitis. Arlington: Natiotional Mastitis Council, Inc. 1999: 11-108
  23. Noguchi JK, Gill MA. Sulbactam: a beta-lactamase inhibitor. Clin Pharm 1988; 7: 37-51
  24. Pak SI, Han HR, Shimizu A. Characterization of methicillinresistant Staphylococcus aureus isolated from dogs in Korea. J Vet Med Sci 1999; 61: 1013-1018 https://doi.org/10.1292/jvms.61.1013
  25. Piddock LJ. Does the use of antimicrobial agents in veterinary medicine and animal husbandry select antibiotic-resistant bacteria that infect man and compromise antimicrobial chemotherapy? J Antimicrob Chemother 1996; 38: 1-3 https://doi.org/10.1093/jac/38.1.1
  26. Randhawa B, Harris EB, Prabhakaran K. Bactericidal action of oral ampicillin/sulbactam against Mycobacterium leprae. J Antimicrob Chemother 1999; 44: 279-281 https://doi.org/10.1093/jac/44.2.279
  27. Retsema JA, English AR, Girard A, Lynch JE, Anderson M, Brennan L, Cimochowski C, Faiella J, Norcia W, Sawyer P. Sulbactam/ampicillin: in vitro spectrum, potency, and activity in models of acute infection. Rev Infect Dis 1986; 8: S528-S534 https://doi.org/10.1093/clinids/8.Supplement_5.S528
  28. Schwiersch U, Lang N, Wildfeuer DA. Concentration of sulbactam and ampicillin in serum and the myometrium. Drugs 1986; 31: 26-28 https://doi.org/10.2165/00003495-198600312-00007
  29. Shryock TR, Apley M, Jones RN , Lein DH, Thornsberry C, Walker RD, Watts JL, White DG, Wu CC. Performance Standards for Antimicrobial disk and Dilution Susceptibility Tests for Bacteria isolated from Animals; NCCLS M31-A2, 2nd ed. Pennsylvania: National Committee for Clinical laboratory Standards. 2002: 13-30
  30. Warnke JP, Wildfeuer A, Eibel G, Pfaff G, Klammer A. Pharmacokinetics of ampicillin/sulbactam in patients undergoing spinal microneurosurgical procedures. Int J Clin Pharmacol Ther 1998; 36: 253-257
  31. Wexler HM, Harris B, Carter WT, Finegold SM. In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria. Antimicrob Agents Chemother 1985; 27: 876-878 https://doi.org/10.1128/AAC.27.5.876
  32. Williams JD. Beta-Lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone. Clin Infect Dis 1997; 24: 494-497 https://doi.org/10.1093/clinids/24.3.494
  33. Williams JD. Beta-lactamases and beta-lactamase inhibitors. Int J Antimicrob Agents 1999; 12: S3-S7
  34. Zhang YL, Li JT. The in vitro activity of sulbactam combined with third generation cephalosporins against third generation cephalosporin-resistant bacteria. Int J Antimicrob Agents 2001; 17: 143-146 https://doi.org/10.1016/S0924-8579(00)00329-0